| Role |
Name |
Disclosure |
Details |
| Author | Robert J Hilt, MD, FAAP, Staff Physician, Department of Child and Adolescent Psychiatry, University of Massachusetts | Nothing to disclose | Details | | Coauthor | W Peter Metz, MD, Associate Professor, Department of Psychiatry and Pediatrics, University of Massachusetts Medical School | Nothing to disclose | Details | | Medical Editor | Alan D Schmetzer, MD, Professor, Vice-Chair for Education, and Director of Residency Training, Department of Psychiatry, Indiana University School of Medicine | Nothing to disclose | Details | | Pharmacy Editor | Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine | Nothing to disclose | Details | | Managing Editor | Eduardo Dunayevich, MD, Adjunct Assistant Professor, Department of Psychiatry, University of Cincinnati; Clinical Research Physician, Neuroscience, Lilly Research Laboratories | Nothing to disclose | Details | | CME Editor | Harold H Harsch, MD, Program Director of Geropsychiatry, Department of Geriatrics/Gerontology, Associate Professor, Department of Psychiatry and Department of Medicine, Froedtert Hospital, Medical College of Wisconsin | lilly BMS Forest Labs AstraZeneca Pfizer Northstar Novartis Pfizer | Details | | Chief Editor | Stephen Soreff, MD, President of Education Initiatives, Nottingham, NH; Faculty, Metropolitan College of Boston University, Boston, MA | Nothing to disclose | Details |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| W Peter Metz, Coauthor |
The contributor discloses no conflict of interest. |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| Eduardo Dunayevich, Managing Editor |
The contributor discloses no conflict of interest. |
|